Real-world use of nirmatrelvir-ritonavir: who benefits?

被引：1
|
作者：
Molina, Kyle C. [1 ,2 ]
Ginde, Adit A. [1 ]
机构：
[1] Colorado Univ, Dept Emergency Med, Sch Med, Aurora, CO 80045 USA
[2] Scripps Hlth, La Jolla, CA 92037 USA
来源：
LANCET INFECTIOUS DISEASES | 2023年 / 23卷 / 07期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/S1473-3099(23)00180-9
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：765 / 767
页数：3
相关论文
共 50 条
  • [21] Nirmatrelvir-ritonavir might only be effective in elderly patients
    Wang, Yu
    Chen, Xubo
    Liu, Xinbing
    Zhao, Danyang
    Feng, Liuliu
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [22] Immunosuppression, nirmatrelvir-ritonavir, and post-COVID condition
    Sparks, Jeffrey A.
    Wallace, Zachary S.
    LANCET RHEUMATOLOGY, 2025, 7 (02): : e77 - e78
  • [23] Real-world effectiveness and safety of oral azvudine versus nirmatrelvir-ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
    Wang, Haiyu
    Cui, Guangying
    Cheng, Ming
    Aji, Tuerganaili
    Li, Guotao
    Hu, Xinjun
    Li, Guangming
    Zhang, Shixi
    Zhang, Yanyang
    Diao, Linqi
    Li, Pan
    Wang, Ling
    Yuan, Yiqiang
    Qian, Guowu
    Zhang, Ruiqing
    Jin, Xiaoli
    Wang, Juan
    Luo, Hong
    Zhang, Donghua
    Wang, Mingming
    Li, Silin
    Song, Zhan
    Yang, Mengzhao
    Su, Guanyue
    Sun, Ranran
    Chang, Junbiao
    Yu, Zujiang
    Ren, Zhigang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [24] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [25] Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments
    Chen, Sylvia
    Leong, Wai Fook
    Lee, Sze Sing
    Chowbay, Balram
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2022, 51 (12) : 752 - 754
  • [26] Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19
    Rowan, Christopher G.
    Nichols, Russell M.
    Dhopeshwarkar, Neil
    Alyea, Jennifer M.
    Zhu, Baojin
    Toh, Sengwee
    Chan, K. Arnold
    Grace, Elsie L.
    PULMONARY THERAPY, 2025, 11 (01) : 55 - 67
  • [27] Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19
    LeBras, Marlys
    Crawley, Alex
    Legge, Marc
    Takaya, Satchan
    Lee, Stephen
    Regier, Loren
    CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : 546 - 549
  • [28] Tacrolimus Level Increase During Nirmatrelvir-Ritonavir Treatment
    Gong, Yinhua
    Li, Yue
    Xue, Ling
    Gao, Jie
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (04) : e458 - e461
  • [29] Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
    Qiu, Ye
    Wen, Hao
    Wang, Haoru
    Sun, Wenjun
    Li, Guangchao
    Li, Shaoqiang
    Wang, Yan
    Zhai, Jingnan
    Zhan, Yangqing
    Su, Yutian
    Long, Zhiwei
    Li, Zhengtu
    Ye, Feng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [30] Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study
    Han, Xiaobo
    Gao, Darui
    Li, Chenglong
    Yuan, Xin
    Cui, Junchang
    Zhao, Weiguo
    Xie, Fei
    Wang, Kaifei
    Liu, Yuhong
    Muo, Guoxin
    Xi, Na
    Zheng, Mengli
    Wang, Rentao
    Xiao, Kun
    Zhao, Dahui
    Zhang, Xinxin
    Han, Xinjie
    Wang, Bo
    Zhang, Tiantian
    Xie, Wuxiang
    Xie, Lixin
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
12345